Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea
Background and Objectives: Obstructive sleep apnoea (OSA) is associated with heightened systemic inflammation and a hypercoagulation state. Soluble urokinase-type plasminogen activator receptor (suPAR) plays a role in fibrinolysis and systemic inflammation. However, suPAR has not been investigated i...
Saved in:
| Published in | Medicina (Kaunas, Lithuania) Vol. 56; no. 2; p. 77 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI
14.02.2020
MDPI AG |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1648-9144 1010-660X 1648-9144 1010-660X |
| DOI | 10.3390/medicina56020077 |
Cover
Loading…
| Abstract | Background and Objectives: Obstructive sleep apnoea (OSA) is associated with heightened systemic inflammation and a hypercoagulation state. Soluble urokinase-type plasminogen activator receptor (suPAR) plays a role in fibrinolysis and systemic inflammation. However, suPAR has not been investigated in OSA. Materials and Methods: A total of 53 patients with OSA and 15 control volunteers participated in the study. Medical history was taken and in-hospital sleep studies were performed. Plasma suPAR levels were determined by ELISA. Results: There was no difference in plasma suPAR values between patients with OSA (2.198 ± 0.675 ng/mL) and control subjects (2.088 ± 0.976 ng/mL, p = 0.62). Neither was there any difference when patients with OSA were divided into mild (2.134 ± 0.799 ng/mL), moderate (2.274 ± 0.597 ng/mL) and severe groups (2.128 ± 0.744 ng/mL, p = 0.84). There was no significant correlation between plasma suPAR and indices of OSA severity, blood results or comorbidities, such as hypertension, diabetes, dyslipidaemia or cardiovascular disease. Plasma suPAR levels were higher in women when all subjects were analysed together (2.487 ± 0.683 vs. 1.895 ± 0.692 ng/mL, p < 0.01), and also separately in controls (2.539 ± 0.956 vs. 1.411 ± 0.534 ng/mL, p = 0.02) and patients (2.467 ± 0.568 vs. 1.991 ± 0.686 ng/mL, p < 0.01). Conclusions: Our results suggest that suPAR does not play a significant role in the pathophysiology of OSA. The significant gender difference needs to be considered when conducting studies on circulating suPAR. |
|---|---|
| AbstractList | Background and Objectives: Obstructive sleep apnoea (OSA) is associated with heightened systemic inflammation and a hypercoagulation state. Soluble urokinase-type plasminogen activator receptor (suPAR) plays a role in fibrinolysis and systemic inflammation. However, suPAR has not been investigated in OSA. Materials and Methods: A total of 53 patients with OSA and 15 control volunteers participated in the study. Medical history was taken and in-hospital sleep studies were performed. Plasma suPAR levels were determined by ELISA. Results: There was no difference in plasma suPAR values between patients with OSA (2.198 ± 0.675 ng/mL) and control subjects (2.088 ± 0.976 ng/mL, p = 0.62). Neither was there any difference when patients with OSA were divided into mild (2.134 ± 0.799 ng/mL), moderate (2.274 ± 0.597 ng/mL) and severe groups (2.128 ± 0.744 ng/mL, p = 0.84). There was no significant correlation between plasma suPAR and indices of OSA severity, blood results or comorbidities, such as hypertension, diabetes, dyslipidaemia or cardiovascular disease. Plasma suPAR levels were higher in women when all subjects were analysed together (2.487 ± 0.683 vs. 1.895 ± 0.692 ng/mL, p < 0.01), and also separately in controls (2.539 ± 0.956 vs. 1.411 ± 0.534 ng/mL, p = 0.02) and patients (2.467 ± 0.568 vs. 1.991 ± 0.686 ng/mL, p < 0.01). Conclusions: Our results suggest that suPAR does not play a significant role in the pathophysiology of OSA. The significant gender difference needs to be considered when conducting studies on circulating suPAR. : Obstructive sleep apnoea (OSA) is associated with heightened systemic inflammation and a hypercoagulation state. Soluble urokinase-type plasminogen activator receptor (suPAR) plays a role in fibrinolysis and systemic inflammation. However, suPAR has not been investigated in OSA. : A total of 53 patients with OSA and 15 control volunteers participated in the study. Medical history was taken and in-hospital sleep studies were performed. Plasma suPAR levels were determined by ELISA. : There was no difference in plasma suPAR values between patients with OSA (2.198 ± 0.675 ng/mL) and control subjects (2.088 ± 0.976 ng/mL, = 0.62). Neither was there any difference when patients with OSA were divided into mild (2.134 ± 0.799 ng/mL), moderate (2.274 ± 0.597 ng/mL) and severe groups (2.128 ± 0.744 ng/mL, = 0.84). There was no significant correlation between plasma suPAR and indices of OSA severity, blood results or comorbidities, such as hypertension, diabetes, dyslipidaemia or cardiovascular disease. Plasma suPAR levels were higher in women when all subjects were analysed together (2.487 ± 0.683 vs. 1.895 ± 0.692 ng/mL, < 0.01), and also separately in controls (2.539 ± 0.956 vs. 1.411 ± 0.534 ng/mL, = 0.02) and patients (2.467 ± 0.568 vs. 1.991 ± 0.686 ng/mL, < 0.01). : Our results suggest that suPAR does not play a significant role in the pathophysiology of OSA. The significant gender difference needs to be considered when conducting studies on circulating suPAR. Background and Objectives : Obstructive sleep apnoea (OSA) is associated with heightened systemic inflammation and a hypercoagulation state. Soluble urokinase-type plasminogen activator receptor (suPAR) plays a role in fibrinolysis and systemic inflammation. However, suPAR has not been investigated in OSA. Materials and Methods : A total of 53 patients with OSA and 15 control volunteers participated in the study. Medical history was taken and in-hospital sleep studies were performed. Plasma suPAR levels were determined by ELISA. Results : There was no difference in plasma suPAR values between patients with OSA (2.198 ± 0.675 ng/mL) and control subjects (2.088 ± 0.976 ng/mL, p = 0.62). Neither was there any difference when patients with OSA were divided into mild (2.134 ± 0.799 ng/mL), moderate (2.274 ± 0.597 ng/mL) and severe groups (2.128 ± 0.744 ng/mL, p = 0.84). There was no significant correlation between plasma suPAR and indices of OSA severity, blood results or comorbidities, such as hypertension, diabetes, dyslipidaemia or cardiovascular disease. Plasma suPAR levels were higher in women when all subjects were analysed together (2.487 ± 0.683 vs. 1.895 ± 0.692 ng/mL, p < 0.01), and also separately in controls (2.539 ± 0.956 vs. 1.411 ± 0.534 ng/mL, p = 0.02) and patients (2.467 ± 0.568 vs. 1.991 ± 0.686 ng/mL, p < 0.01). Conclusions : Our results suggest that suPAR does not play a significant role in the pathophysiology of OSA. The significant gender difference needs to be considered when conducting studies on circulating suPAR. Background and Objectives: Obstructive sleep apnoea (OSA) is associated with heightened systemic inflammation and a hypercoagulation state. Soluble urokinase-type plasminogen activator receptor (suPAR) plays a role in fibrinolysis and systemic inflammation. However, suPAR has not been investigated in OSA. Materials and Methods: A total of 53 patients with OSA and 15 control volunteers participated in the study. Medical history was taken and in-hospital sleep studies were performed. Plasma suPAR levels were determined by ELISA. Results: There was no difference in plasma suPAR values between patients with OSA (2.198 ± 0.675 ng/mL) and control subjects (2.088 ± 0.976 ng/mL, p = 0.62). Neither was there any difference when patients with OSA were divided into mild (2.134 ± 0.799 ng/mL), moderate (2.274 ± 0.597 ng/mL) and severe groups (2.128 ± 0.744 ng/mL, p = 0.84). There was no significant correlation between plasma suPAR and indices of OSA severity, blood results or comorbidities, such as hypertension, diabetes, dyslipidaemia or cardiovascular disease. Plasma suPAR levels were higher in women when all subjects were analysed together (2.487 ± 0.683 vs. 1.895 ± 0.692 ng/mL, p < 0.01), and also separately in controls (2.539 ± 0.956 vs. 1.411 ± 0.534 ng/mL, p = 0.02) and patients (2.467 ± 0.568 vs. 1.991 ± 0.686 ng/mL, p < 0.01). Conclusions: Our results suggest that suPAR does not play a significant role in the pathophysiology of OSA. The significant gender difference needs to be considered when conducting studies on circulating suPAR.Background and Objectives: Obstructive sleep apnoea (OSA) is associated with heightened systemic inflammation and a hypercoagulation state. Soluble urokinase-type plasminogen activator receptor (suPAR) plays a role in fibrinolysis and systemic inflammation. However, suPAR has not been investigated in OSA. Materials and Methods: A total of 53 patients with OSA and 15 control volunteers participated in the study. Medical history was taken and in-hospital sleep studies were performed. Plasma suPAR levels were determined by ELISA. Results: There was no difference in plasma suPAR values between patients with OSA (2.198 ± 0.675 ng/mL) and control subjects (2.088 ± 0.976 ng/mL, p = 0.62). Neither was there any difference when patients with OSA were divided into mild (2.134 ± 0.799 ng/mL), moderate (2.274 ± 0.597 ng/mL) and severe groups (2.128 ± 0.744 ng/mL, p = 0.84). There was no significant correlation between plasma suPAR and indices of OSA severity, blood results or comorbidities, such as hypertension, diabetes, dyslipidaemia or cardiovascular disease. Plasma suPAR levels were higher in women when all subjects were analysed together (2.487 ± 0.683 vs. 1.895 ± 0.692 ng/mL, p < 0.01), and also separately in controls (2.539 ± 0.956 vs. 1.411 ± 0.534 ng/mL, p = 0.02) and patients (2.467 ± 0.568 vs. 1.991 ± 0.686 ng/mL, p < 0.01). Conclusions: Our results suggest that suPAR does not play a significant role in the pathophysiology of OSA. The significant gender difference needs to be considered when conducting studies on circulating suPAR. |
| Author | Meszaros, Martina Lazar, Zsofia Bocskei, Renata Marietta Kunos, Laszlo Bikov, Andras Tarnoki, Adam Domonkos Tarnoki, David Laszlo |
| AuthorAffiliation | 4 North West Lung Centre, Manchester University NHS Foundation Trust, Manchester M23 9LT, UK 3 Medical Imaging Centre, Semmelweis University, 1082 Budapest, Hungary; tarnoki2@gmail.com (A.D.T.); tarnoki4@gmail.com (D.L.T.) 2 Department of Pulmonology, Szent Borbala County Hospital, 2800 Tatabánya, Hungary 1 Department of Pulmonology, Semmelweis University, 1083 Budapest, Hungary; drbocskeirenata@gmail.com (R.M.B.); martina.meszaros1015@gmail.com (M.M.) |
| AuthorAffiliation_xml | – name: 2 Department of Pulmonology, Szent Borbala County Hospital, 2800 Tatabánya, Hungary – name: 4 North West Lung Centre, Manchester University NHS Foundation Trust, Manchester M23 9LT, UK – name: 1 Department of Pulmonology, Semmelweis University, 1083 Budapest, Hungary; drbocskeirenata@gmail.com (R.M.B.); martina.meszaros1015@gmail.com (M.M.) – name: 3 Medical Imaging Centre, Semmelweis University, 1082 Budapest, Hungary; tarnoki2@gmail.com (A.D.T.); tarnoki4@gmail.com (D.L.T.) |
| Author_xml | – sequence: 1 givenname: Renata Marietta orcidid: 0000-0001-5461-6730 surname: Bocskei fullname: Bocskei, Renata Marietta – sequence: 2 givenname: Martina surname: Meszaros fullname: Meszaros, Martina – sequence: 3 givenname: Adam Domonkos surname: Tarnoki fullname: Tarnoki, Adam Domonkos – sequence: 4 givenname: David Laszlo surname: Tarnoki fullname: Tarnoki, David Laszlo – sequence: 5 givenname: Laszlo surname: Kunos fullname: Kunos, Laszlo – sequence: 6 givenname: Zsofia orcidid: 0000-0003-2444-9040 surname: Lazar fullname: Lazar, Zsofia – sequence: 7 givenname: Andras surname: Bikov fullname: Bikov, Andras |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32075014$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kstr3DAQxk1JaR7tvafiYy_bynpYq0thWfoIBFKa5FjEeHa0VaqVXMkO5L-vnU1KEuhJg-b7fh_MzHF1EFOkqnrbsA9CGPZxRxuPPoJqGWdM6xfVUdPK5cI0Uh48qg-r41KuGRNcaf6qOhScacUaeVT9XPuMY4DBx219kcLYBaqvcvo9UQstLm97qr8HKDsf05ZivcLB38CQcv2DkPq58LE-78qQx7lF9UUg6utVHxPB6-qlg1Dozf17Ul19-Xy5_rY4O_96ul6dLVC2fFi0SGg61JqB47B0qEgsCYzaQGuka7RwTim9bIHjkgvXCaeMaEGjU6AQxUl1uuduElzbPvsd5FubwNu7j5S3FvLgMZDVUjJtOq6cJunAdI2GBrk2aIxGySfWpz2rH7tpvkhxyBCeQJ92ov9lt-nGanbHngDv7wE5_RmpDHbnC1IIECmNxXKhjGRKqFn67nHWv5CH_UyCdi_AnErJ5Cz6YVpWmqN9sA2z8yHY54cwGdkz4wP7v5a_Eu66OA |
| CitedBy_id | crossref_primary_10_3390_medicina56050208 crossref_primary_10_3390_life11040362 crossref_primary_10_3390_ijms22062834 crossref_primary_10_1111_idh_12882 crossref_primary_10_1177_20587384211048561 |
| Cites_doi | 10.1164/rccm.201808-1509OC 10.4187/respcare.03571 10.1016/j.cca.2015.02.031 10.1042/bj3100345 10.1016/j.smrv.2007.11.003 10.1007/s00408-018-0120-z 10.1136/thx.2003.018739 10.1016/j.atherosclerosis.2018.01.029 10.1111/j.1365-2796.2011.02372.x 10.1016/j.atherosclerosis.2014.08.035 10.1111/j.1582-4934.2009.00721.x 10.1007/s00408-019-00211-w 10.1016/j.resp.2011.03.015 10.1002/jmv.21114 10.1111/j.1365-2796.2010.02252.x 10.1016/S0021-9258(18)31492-3 10.1111/jsr.12674 10.1183/13993003.00893-2018 10.5664/jcsm.2172 10.1160/TH15-03-0206 10.1002/lary.26789 10.1038/ijir.2012.20 10.1016/j.smrv.2016.10.004 10.4049/jimmunol.152.2.505 10.1089/rej.2019.2183 10.1159/000324587 10.1016/j.ijcard.2012.03.040 10.1186/1741-7015-10-2 10.1055/s-0037-1616105 10.1093/aje/kws342 10.1161/JAHA.114.001118 10.1038/nrcardio.2010.145 10.3758/BRM.41.4.1149 10.1371/journal.pone.0166725 10.1155/2009/504294 10.5665/sleep.3414 |
| ContentType | Journal Article |
| Copyright | 2020 by the authors. 2020 |
| Copyright_xml | – notice: 2020 by the authors. 2020 |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3390/medicina56020077 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1648-9144 1010-660X |
| ExternalDocumentID | oai_doaj_org_article_744079b25f7e4fa9b17a1c279c997c42 PMC7074407 32075014 10_3390_medicina56020077 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Hungarian Respiratory Society grantid: to Andras Bikov and David L. Tarnoki – fundername: Semmelweis University grantid: to Laszlo Kunos |
| GroupedDBID | 0R~ 29M 2WC 4.4 457 53G 5GY 5VS 7X7 8FI 8FJ AADQD AAEDT AAFWJ AAIKJ AAYXX ABMAC ABUWG ACGFS ADBBV ADEZE AFKRA AFPKN AFZYC AGHFR AHDRD ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR CCPQU CITATION F5P FDB FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR KQ8 MODMG O9- OK1 OVT PGMZT PHGZM PHGZT PIMPY RPM UKHRP XSB 0SF AACTN DIK NPM 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c462t-6cec9bc770af2a8fc5e38ea95da694f173ff55786a2c823fb3f5936a7cf5a5cc3 |
| IEDL.DBID | DOA |
| ISSN | 1648-9144 1010-660X |
| IngestDate | Wed Aug 27 01:26:54 EDT 2025 Thu Aug 21 18:31:18 EDT 2025 Fri Jul 11 10:16:33 EDT 2025 Thu Jan 02 22:59:36 EST 2025 Thu Apr 24 23:10:44 EDT 2025 Tue Jul 01 02:41:34 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | fibrinolysis inflammation sleep disordered breathing biomarkers OSAHS |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c462t-6cec9bc770af2a8fc5e38ea95da694f173ff55786a2c823fb3f5936a7cf5a5cc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-5461-6730 0000-0003-2444-9040 |
| OpenAccessLink | https://doaj.org/article/744079b25f7e4fa9b17a1c279c997c42 |
| PMID | 32075014 |
| PQID | 2359405357 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_744079b25f7e4fa9b17a1c279c997c42 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7074407 proquest_miscellaneous_2359405357 pubmed_primary_32075014 crossref_citationtrail_10_3390_medicina56020077 crossref_primary_10_3390_medicina56020077 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20200214 |
| PublicationDateYYYYMMDD | 2020-02-14 |
| PublicationDate_xml | – month: 2 year: 2020 text: 20200214 day: 14 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Medicina (Kaunas, Lithuania) |
| PublicationTitleAlternate | Medicina (Kaunas) |
| PublicationYear | 2020 |
| Publisher | MDPI MDPI AG |
| Publisher_xml | – name: MDPI – name: MDPI AG |
| References | Bocskei (ref_25) 2019; 197 Berry (ref_24) 2012; 8 Nykjaer (ref_14) 1994; 152 Thuno (ref_13) 2009; 27 Lin (ref_33) 2008; 12 Kent (ref_1) 2011; 178 Malan (ref_23) 2016; 115 Baran (ref_27) 2009; 13 Shetty (ref_30) 1998; 274 ref_12 Tsai (ref_34) 2018; 128 Enocsson (ref_11) 2015; 444 Kunos (ref_3) 2018; 196 Mazzotti (ref_37) 2019; 200 Kohler (ref_10) 2010; 7 (ref_16) 2011; 270 Lyngbaek (ref_20) 2013; 167 Bagai (ref_5) 2014; 37 Chiu (ref_38) 2017; 36 Steffanina (ref_8) 2015; 60 Diederichsen (ref_19) 2018; 271 Lund (ref_29) 1995; 310 Horvath (ref_2) 2018; 27 Masucci (ref_17) 1991; 266 Sorensen (ref_31) 2014; 237 Eapen (ref_18) 2014; 3 Andersen (ref_35) 2008; 80 Andersen (ref_36) 2010; 268 Peppard (ref_22) 2013; 177 Robinson (ref_7) 2004; 59 Chavakis (ref_15) 2001; 86 Cancello (ref_21) 2011; 4 Stavaras (ref_28) 2012; 24 ref_9 Guan (ref_32) 2002; 81 Faul (ref_26) 2009; 41 ref_4 ref_6 |
| References_xml | – volume: 200 start-page: 493 year: 2019 ident: ref_37 article-title: Symptom Subtypes of Obstructive Sleep Apnea Predict Incidence of Cardiovascular Outcomes publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.201808-1509OC – volume: 60 start-page: 1643 year: 2015 ident: ref_8 article-title: The Plasminogen System and Transforming Growth Factor-beta in Subjects With Obstructive Sleep Apnea Syndrome: Effects of CPAP Treatment publication-title: Respir. Care doi: 10.4187/respcare.03571 – volume: 444 start-page: 234 year: 2015 ident: ref_11 article-title: Soluble urokinase plasminogen activator receptor—A valuable biomarker in systemic lupus erythematosus? publication-title: Clin. Chim. Acta Int. J. Clin. Chem. doi: 10.1016/j.cca.2015.02.031 – volume: 310 start-page: 345 year: 1995 ident: ref_29 article-title: Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549 publication-title: Biochem. J. doi: 10.1042/bj3100345 – volume: 12 start-page: 481 year: 2008 ident: ref_33 article-title: Gender differences in obstructive sleep apnea and treatment implications publication-title: Sleep Med. Rev. doi: 10.1016/j.smrv.2007.11.003 – volume: 196 start-page: 417 year: 2018 ident: ref_3 article-title: Circulating Survivin Levels in Obstructive Sleep Apnoea publication-title: Lung doi: 10.1007/s00408-018-0120-z – volume: 59 start-page: 777 year: 2004 ident: ref_7 article-title: Circulating cardiovascular risk factors in obstructive sleep apnoea: Data from randomised controlled trials publication-title: Thorax doi: 10.1136/thx.2003.018739 – volume: 271 start-page: 245 year: 2018 ident: ref_19 article-title: Prognostic value of suPAR and hs-CRP on cardiovascular disease publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2018.01.029 – volume: 270 start-page: 29 year: 2011 ident: ref_16 article-title: suPAR—A future risk marker in bacteremia publication-title: J. Intern. Med. doi: 10.1111/j.1365-2796.2011.02372.x – volume: 237 start-page: 60 year: 2014 ident: ref_31 article-title: Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2014.08.035 – volume: 81 start-page: 389 year: 2002 ident: ref_32 article-title: Effects of hormones on uPA, PAI-1 and suPAR from cultured endometrial and ovarian endometriotic stromal cells publication-title: Acta Obstet. Gynecol. Scand. – volume: 13 start-page: 3797 year: 2009 ident: ref_27 article-title: Survivin is an essential mediator of arthritis interacting with urokinase signalling publication-title: J. Cell. Mol. Med. doi: 10.1111/j.1582-4934.2009.00721.x – volume: 197 start-page: 189 year: 2019 ident: ref_25 article-title: Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD publication-title: Lung doi: 10.1007/s00408-019-00211-w – volume: 178 start-page: 475 year: 2011 ident: ref_1 article-title: Obstructive sleep apnea and inflammation: Relationship to cardiovascular co-morbidity publication-title: Respir. Physiol. Neurobiol. doi: 10.1016/j.resp.2011.03.015 – volume: 80 start-page: 209 year: 2008 ident: ref_35 article-title: Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy publication-title: J. Med Virol. doi: 10.1002/jmv.21114 – volume: 268 start-page: 296 year: 2010 ident: ref_36 article-title: Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population publication-title: J. Intern. Med. doi: 10.1111/j.1365-2796.2010.02252.x – volume: 266 start-page: 8655 year: 1991 ident: ref_17 article-title: A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(18)31492-3 – volume: 27 start-page: e12674 year: 2018 ident: ref_2 article-title: Complement system activation in obstructive sleep apnea publication-title: J. Sleep Res. doi: 10.1111/jsr.12674 – ident: ref_9 doi: 10.1183/13993003.00893-2018 – volume: 8 start-page: 597 year: 2012 ident: ref_24 article-title: Rules for scoring respiratory events in sleep: Update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine publication-title: J. Clin. Sleep Med. Off. Publ. Am. Acad. Sleep Med. doi: 10.5664/jcsm.2172 – volume: 115 start-page: 63 year: 2016 ident: ref_23 article-title: Three-year changes of prothrombotic factors in a cohort of South Africans with a high clinical suspicion of obstructive sleep apnea publication-title: Thromb. Haemost. doi: 10.1160/TH15-03-0206 – volume: 128 start-page: 763 year: 2018 ident: ref_34 article-title: Sleep apnea and risk of vertigo: A nationwide population-based cohort study publication-title: Laryngoscope doi: 10.1002/lary.26789 – volume: 24 start-page: 228 year: 2012 ident: ref_28 article-title: Sexual function in pre- and post-menopausal women with obstructive sleep apnea syndrome publication-title: Int. J. Impot. Res. doi: 10.1038/ijir.2012.20 – volume: 36 start-page: 57 year: 2017 ident: ref_38 article-title: Diagnostic accuracy of the Berlin questionnaire, STOP-BANG, STOP, and Epworth sleepiness scale in detecting obstructive sleep apnea: A bivariate meta-analysis publication-title: Sleep Med. Rev. doi: 10.1016/j.smrv.2016.10.004 – volume: 152 start-page: 505 year: 1994 ident: ref_14 article-title: Urokinase receptor. An activation antigen in human T lymphocytes publication-title: J. Immunol. (Baltim. Md. 1950) doi: 10.4049/jimmunol.152.2.505 – ident: ref_4 doi: 10.1089/rej.2019.2183 – volume: 274 start-page: L871 year: 1998 ident: ref_30 article-title: A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells publication-title: Am. J. Physiol. – volume: 4 start-page: 17 year: 2011 ident: ref_21 article-title: Urokinase plasminogen activator receptor in adipose tissue macrophages of morbidly obese subjects publication-title: Obes. Facts doi: 10.1159/000324587 – volume: 167 start-page: 781 year: 2013 ident: ref_20 article-title: CRP and suPAR are differently related to anthropometry and subclinical organ damage publication-title: Int. J. Cardiol. doi: 10.1016/j.ijcard.2012.03.040 – ident: ref_12 doi: 10.1186/1741-7015-10-2 – volume: 86 start-page: 686 year: 2001 ident: ref_15 article-title: Release of soluble urokinase receptor from vascular cells publication-title: Thromb. Haemost. doi: 10.1055/s-0037-1616105 – volume: 177 start-page: 1006 year: 2013 ident: ref_22 article-title: Increased prevalence of sleep-disordered breathing in adults publication-title: Am. J. Epidemiol. doi: 10.1093/aje/kws342 – volume: 3 start-page: e001118 year: 2014 ident: ref_18 article-title: Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events publication-title: J. Am. Heart Assoc. doi: 10.1161/JAHA.114.001118 – volume: 7 start-page: 677 year: 2010 ident: ref_10 article-title: Mechanisms of vascular damage in obstructive sleep apnea publication-title: Nat. Rev. Cardiol. doi: 10.1038/nrcardio.2010.145 – volume: 41 start-page: 1149 year: 2009 ident: ref_26 article-title: Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses publication-title: Behav. Res. Methods doi: 10.3758/BRM.41.4.1149 – ident: ref_6 doi: 10.1371/journal.pone.0166725 – volume: 27 start-page: 157 year: 2009 ident: ref_13 article-title: suPAR: The molecular crystal ball publication-title: Dis. Markers doi: 10.1155/2009/504294 – volume: 37 start-page: 359 year: 2014 ident: ref_5 article-title: Circadian variability of fibrinolytic markers and endothelial function in patients with obstructive sleep apnea publication-title: Sleep doi: 10.5665/sleep.3414 |
| SSID | ssj0032572 |
| Score | 2.1991532 |
| Snippet | Background and Objectives: Obstructive sleep apnoea (OSA) is associated with heightened systemic inflammation and a hypercoagulation state. Soluble... : Obstructive sleep apnoea (OSA) is associated with heightened systemic inflammation and a hypercoagulation state. Soluble urokinase-type plasminogen activator... Background and Objectives : Obstructive sleep apnoea (OSA) is associated with heightened systemic inflammation and a hypercoagulation state. Soluble... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 77 |
| SubjectTerms | biomarkers fibrinolysis inflammation osahs sleep disordered breathing |
| Title | Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32075014 https://www.proquest.com/docview/2359405357 https://pubmed.ncbi.nlm.nih.gov/PMC7074407 https://doaj.org/article/744079b25f7e4fa9b17a1c279c997c42 |
| Volume | 56 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA9aQXwRv72qRwRffFium6_ZfbyWliK0FvXgXmRJshM9PLPHtfbvd5LdO3pF9MW3ZTdLhplfMjOZ8BvG3nna4cDotki01IXytKQqcpyFbUvt0BrlMh3D2bk5nakPcz2_0eor3Qnr6YF7xU0SgR3UTugAqIKtXQm29AJqmgW8yrsv-bxNMtXvwZKAKPqipKSkfjLUqS2593Q2BztOKHP1_ynAvH1P8objOXnEHg4RI5_2kj5mdzA-YffPhpr4U_b1aLH2uQlX_MbTKZdbIp-tux8kySUWKdHkFxQj_1zEjtDCpz53NOvWnEJGXKWHReQf3cAke4388xJxxaer2KF9xmYnx1-OTouhaULhlRFXhfHoa-cBDmwQtgpeo6zQ1rq1plahBBmCpmVqrPCVkMHJkJr6WfBBW-29fM72YhfxJeNVIEW2rnK-TTR9ujI1ooKAJRgAhBGbbLTY-IFRPDW2WDaUWSS9N7f1PmLvt3-sejaNv4w9TIbZjks82PkFoaMZ0NH8Cx0j9nZj1obWTSqG2Ijdr8tGSF2rRG5DE73ozbydSooUSJVqxGAHADuy7H6Ji--ZmxsOskj7_0P4V-yBSNl9aj-jXrM9ggG-oRDoyo3ZXZjDmN07PD6_-DTO2P8NF28JpA |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Circulating+Soluble+Urokinase-Type+Plasminogen+Activator+Receptor+in+Obstructive+Sleep+Apnoea&rft.jtitle=Medicina+%28Kaunas%2C+Lithuania%29&rft.au=Bocskei%2C+Renata+Marietta&rft.au=Meszaros%2C+Martina&rft.au=Tarnoki%2C+Adam+Domonkos&rft.au=Tarnoki%2C+David+Laszlo&rft.date=2020-02-14&rft.pub=MDPI&rft.issn=1010-660X&rft.eissn=1648-9144&rft.volume=56&rft.issue=2&rft_id=info:doi/10.3390%2Fmedicina56020077&rft_id=info%3Apmid%2F32075014&rft.externalDocID=PMC7074407 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1648-9144&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1648-9144&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1648-9144&client=summon |